Hashemian MN, et al. - Experts sought to assess the effectiveness of topical tacrolimus 0.05% as adjuvant therapy to corticosteroids for treating the acute endothelial rejection of a penetrating keratoplasty (PKP) graft. The resolution of endothelial rejection of a PKP graft could be hastened by the topical tacrolimus 0.05% as an adjunct to steroids and potentially decreased the recurrence of rejection. Nevertheless, the rejection reversal success could not be improved by it.